Results 221 to 230 of about 960,877 (309)

Prevalence of pregnancy and birth outcomes following biologic exposure in immune‐mediated inflammatory diseases: A population‐based study

British Journal of Clinical Pharmacology, EarlyView.
Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman, Lisiane F. Leal, Gabra Nohmie, Anick Bérard   +3 more
wiley   +1 more source

Patient-Provider Distance in Medicare Outpatient Oncology Telehealth Versus Office Visits, 2021-2023: Cross-Sectional Claims Analysis. [PDF]

JMIR Med Inform
Liu L, Onega T, Moen EL, Tosteson ANA, Smith RE, Wang Q, Cowan L, Wang F.   +7 more
europepmc   +1 more source

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

British Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich, Franziska Friedrich, Daniel Soriano, Jona Gjeloshi, Björn C. Frye, Xuan Phuoc Nguyen, Lydia Herbstritt, Caroline von Spee‐Mayer, Britta Lang, Fabrice Nollevaux, Andreas Hoheisel, Dorothee Winterberg, Armin Braun, Thomas Epting, Christine Contini, Karl Winkler, Thomas Reinheckel, Franziska C. Trudzinski, Gernot Rohde, Daiana Stolz, Robert Bals, Martin J. Hug, Sebastian Wirtz, Christoph Peters, Carolin Jenkner   +24 more
wiley   +1 more source

Defining a comprehensive set of value assessment criteria for funders of drug repurposing initiatives

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aims to develop a structured list of value assessment criteria for drug repurposing (DR) projects designed to support consistent, evidence‐informed decision‐making by funders. The assessment criteria were developed within the REMEDi4ALL project, a multi‐stakeholder Horizon Europe funded initiative to advance DR and were validated ...
Dalma Hosszú, Kristóf Gyöngyösi, András Perényi, Helene G. van der Meer, Dunja Huijbers, Pan Pantziarka, András Inotai, Donald C. Lo, Rick Thompson, Zoltán Kaló, Marcell Csanádi   +10 more
wiley   +1 more source

Analysis of trends in the spectrum of oral diseases at the Chinese level‑II hospital for peacekeeping: A case study from the Democratic Republic of the Congo. [PDF]

PLoS One
Zhang Y, Niu J, Chen G, Qin D, Li X, Xu L, Li Z, Xue W.   +7 more
europepmc   +1 more source

Evaluating the Zero-Markup Drug Policy's Effects on Financial Burden and Pharmaceutical Channel Migration: A Structural Variation and Interrupted Time Series Analysis from Hubei, China. [PDF]

J Healthc Leadersh
Zhou Y, Lin K, Xiang L.
europepmc   +1 more source